Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Foreman

Nurse Practitioner, Family Hampton, VA Nurse Practitioner

NPI 1457776684 CMS profile 10799888

2315 W Mercury Blvd # Va007, Hampton, VA 23666

Open in the dashboard

General payments

$17,773

644 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Foreman of Hampton, VA is reported in the CMS Open Payments database as having received $17,773 across 644 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,739 152
2024 General $6,956 169
2023 General $3,617 161
2022 General $2,236 96
2021 General $1,225 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Foreman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Foreman were reported at $3,739. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Foreman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,225 $124 $35–$379 $132
2022 $2,236 $141 $44–$430 $149
2023 $3,617 $154 $49–$476 $160
2024 $6,956 $165 $51–$504 $164
2025 $3,739 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ANI Pharmaceuticals, Inc. $3,687 31 payments
  2. AstraZeneca Pharmaceuticals LP $2,732 69 payments
  3. GlaxoSmithKline, LLC. $1,800 103 payments
  4. Jazz Pharmaceuticals Inc. $1,156 45 payments
  5. Regeneron Healthcare Solutions, Inc. $1,016 44 payments
  6. Amgen Inc. $946 39 payments
  7. Genzyme Corporation $928 35 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $763 39 payments
  9. Mallinckrodt Hospital Products Inc. $589 29 payments
  10. Harmony Biosciences LLC $522 32 payments
  11. Other $3,634 178 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,292 628 payments
  2. Honoraria $1,663 1 payment
  3. Travel and Lodging $1,594 11 payments
  4. Education $224 4 payments
Products named General payments · program years 2021–2025
  1. PURIFIED CORTROPHIN GEL $3,488 21 payments
  2. TEZSPIRE Respiratory $1,449 15 payments
  3. FASENRA $1,396 26 payments
  4. BREZTRI $1,258 17 payments
  5. NUCALA $1,131 56 payments
  6. AIRSUPRA $1,034 18 payments
  7. XYWAV $985 39 payments
  8. TEZSPIRE Inflammation $946 39 payments
  9. DUPIXENT Immunology $928 35 payments
  10. DUPIXENT Inflammation And Immunology $781 30 payments
  11. Other $7,522 400 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,849

Median for Nurse Practitioner: 389

Drug cost

$1,241,868

Median for Nurse Practitioner: $21,885

Branded share of claims

58.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tezspire Tezepelumab-Ekko Brand 96 $409,607
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 486 $380,817
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 125 $93,483
Nucala Mepolizumab Brand 19 $79,686
Spiriva Respimat Tiotropium Bromide Brand 98 $67,517
Breo Ellipta Fluticasone/Vilanterol Brand 98 $46,449
Eliquis Apixaban Brand 20 $20,085
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 28 $19,014
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 25 $14,386
Symbicort Budesonide/Formoterol Fumarate Brand 43 $13,801

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$9,616

Medicare's payments for the services billed

Medicare patients

118

Average age 73

Services billed

152

60 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 43%
Ischemic heart disease 36%
Atrial fibrillation 36%
COPD 34%
Heart failure 31%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
$3,465 — —
XYWAV
$466 — —
DUPIXENT
$393 — —
TEZSPIRE
$262 96 —
NUCALA
$232 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

644 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record